As part of a strategic reorganization, the American cotton manufacturer U.S. Cotton has sold the Flawil-based producer of absorbent cotton and other products, FLAWA Consumer, to members of its management. Homburger advised U.S.
Tags :Daniel Häusermann
Santhera Pharmaceuticals Holding has announced the grant of an exclusive North America license for the commercialization of vamorolone to Catalyst Pharmaceuticals for a total consideration of up to USD 231 million
Santhera Pharmaceuticals Holding announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management to provide up to CHF 22.2 million in aggregate, subject to certain milestones
ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a
StoneX Group, a global financial services company, announced that it had acquired Cotton Distributors (CDI). CDI operates a global cotton merchant business and is headquartered in Lausanne with an office in Brazil. Homburger advised StoneX
MCH Group, a renowed international live marketing company, has announced the result of its rights offering. The company will realise gross proceeds totalling CHF 76.9 million. MCH Group continues to have a stable, long-term anchor shareholder
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
Sunrise UPC and CH Media entered into a long-term strategic partnership to drive the expansion of CH Media’s Swiss streaming service «oneplus» and to significantly enhance the portfolio and customer offering of Sunrise UPC.
CSL Limited, a global biotechnology company based in Australia and Vifor Pharma, a Swiss-based global pharmaceutical company, entered into an agreement for CSL to launch an all-cash public tender offer to acquire all publicly held
Novartis has entered into an agreement to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a consideration of USD 20.7 billion. Novartis had acquired the stake between 2001 and 2003 for approximately USD 5
